Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading.

biopsy cell nest size cellular dissociation grading lung squamous cell carcinoma tumour budding

Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
11 2022
Historique:
revised: 08 08 2022
received: 01 06 2022
accepted: 31 08 2022
pubmed: 17 9 2022
medline: 12 10 2022
entrez: 16 9 2022
Statut: ppublish

Résumé

Grading of squamous cell carcinomas (SCCs) based on tumour budding and cell nest size has been termed cellular dissociation grading (CDG) and was suggested as a robust outcome predictor when assessed in biopsies and resections of various extrapulmonary SCCs. In pulmonary SCC (pSCC), this has so far been shown only for resected cancers. As most lung cancers are inoperable, it is of utmost importance to clarify whether the prognostic impact of CDG is retained in the biopsy setting. Two independent pSCC biopsy cohorts from Munich (n = 134, non-resected) and Heidelberg (n = 135, resected) were assessed. Tumour budding and cell nest size measures were assembled into the three-tiered CDG system (G1-G3). Data were correlated with clinicopathological parameters and overall- (OS), disease-specific- (DSS), and disease-free survival (DFS). Interobserver variability and concordance between biopsy and resection specimen were also investigated. CDG was highly congruent between biopsy and resection specimens (κ = 0.77, p < 0.001). In both pSCC cohorts, biopsy-derived CDG strongly impacted on OS, DSS, and DFS (e.g. DFS: p < 0.001). In multivariate survival analyses, CDG remained a stage independent predictor of survival in both cohorts (DFS: p < 0.001 respectively; hazard ratio Munich cohort: CDG-G2: 4.31, CDG-G3; 5.14; Heidelberg cohort: CDG-G2: 5.87, CDG-G3: 9.07). Interobserver agreement for CDG was almost perfect (κ = 0.84, p < 0.001). We conclude that assessment of CDG based on tumour budding and cell nest size is feasible on pSCC biopsies and harbours stage independent prognostic information in resectable as well as non-resectable pSCC. Integration of this grading approach into clinicopathological routine should be considered.

Identifiants

pubmed: 36111649
doi: 10.1002/cjp2.295
pmc: PMC9535098
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

567-578

Informations de copyright

© 2022 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

Références

Histopathology. 2020 Aug;77(2):173-180
pubmed: 31943337
Thorac Surg Clin. 2021 Nov;31(4):379-391
pubmed: 34696850
Lung Cancer. 2020 Jan;139:1-8
pubmed: 31683225
Breast Cancer Res. 2010;12(4):207
pubmed: 20804570
J Pathol. 1992 Apr;166(4):375-81
pubmed: 1517891
J Oral Pathol Med. 2020 Aug;49(7):630-635
pubmed: 31899572
Am J Surg Pathol. 2017 Jun;41(6):750-760
pubmed: 28248819
Am J Surg Pathol. 2019 Mar;43(3):303-313
pubmed: 30475254
J Clin Med. 2016 Apr 29;5(5):
pubmed: 27136592
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
Eur Respir J. 2016 Mar;47(3):938-46
pubmed: 26541540
Pathologe. 2019 Jul;40(4):436-442
pubmed: 31243550
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Br J Cancer. 2020 Mar;122(6):835-846
pubmed: 31937923
Am J Surg Pathol. 2005 Feb;29(2):167-78
pubmed: 15644773
Am J Surg Pathol. 2019 May;43(5):618-627
pubmed: 30807302
J Pathol Clin Res. 2018 Apr;4(2):93-102
pubmed: 29665323
Am J Surg Pathol. 2017 Aug;41(8):1112-1120
pubmed: 28505009
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
J Immunol. 2019 Jan 1;202(1):278-291
pubmed: 30530592
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Int J Oral Maxillofac Surg. 2015 Feb;44(2):143-50
pubmed: 25457829
Head Neck. 2019 Jun;41(6):1918-1927
pubmed: 30620425
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
Br J Cancer. 2019 Dec;121(12):1050-1057
pubmed: 31690830
J Clin Oncol. 2012 May 1;30(13):1438-46
pubmed: 22393100
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
J Thorac Oncol. 2014 Aug;9(8):1126-39
pubmed: 24942260
Am J Surg Pathol. 2020 Sep;44(9):1151-1160
pubmed: 32452873
Histopathology. 2017 Jun;70(7):1125-1137
pubmed: 28122134
Pancreatology. 2018 Jan;18(1):79-84
pubmed: 29233500
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
J Clin Pathol. 2019 Apr;72(4):285-294
pubmed: 30530818
Mod Pathol. 2022 Apr;35(4):524-532
pubmed: 34593968
Mod Pathol. 2020 May;33(5):802-811
pubmed: 31796876
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Moritz Jesinghaus (M)

Institute of Pathology, University Hospital Marburg, Marburg, Germany.
Institute of Pathology, Technical University Munich, Munich, Germany.

Melanie Boxberg (M)

Institute of Pathology, Technical University Munich, Munich, Germany.
Institute of Pathology Munich North, Munich, Germany.

Maxime Schmitt (M)

Institute of Pathology, University Hospital Marburg, Marburg, Germany.
Institute of Pathology, Technical University Munich, Munich, Germany.

Mark Kriegsmann (M)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Alexander Harms (A)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Corinna Lang (C)

Institute of Pathology, Technical University Munich, Munich, Germany.

Thomas Muley (T)

Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany.
Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.

Hauke Winter (H)

Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany.
Department of Thoracic Surgery, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.

Katharina Kriegsmann (K)

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Arne Warth (A)

Institute of Pathology, Wetzlar, Germany.

Albrecht Stenzinger (A)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Carsten Denkert (C)

Institute of Pathology, University Hospital Marburg, Marburg, Germany.

Hans Hoffmann (H)

Department of Thoracic Surgery, Klinikum Rechts der Isar (MRI), Munich, Germany.

Seyer Safi (S)

Department of Thoracic Surgery, Klinikum Rechts der Isar (MRI), Munich, Germany.

Wilko Weichert (W)

Institute of Pathology, Technical University Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, Heidelberg, Germany.
Comprehensive Cancer Center Munich (CCCM), Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH